ZD0473 treatment in lung cancer: an overview of the clinical trial results

References 

1. Quinn M, Babb P, Brock A, Kirkby L, Jones J. Cancer Trends in England and Wales. London: The Stationary Office; 2001;
2. American Cancer Society . Cancer facts and figures. 2001; Washington, DC
3. National Cancer Institute PDQ Statement . Small cell lung cancer (PDQ): treatment - health professionals. January 2002;
4. Jassem J. Chemotheraphy of advanced non-small-cell lung cancer. Ann Oncol. 1999;10:S77–S82
   • CrossRef
5. Rivera MP. Management of patients with advanced non-small-cell lung cancer. Curr Opin Pulm Med. 2001;7:247–251
   • MEDLINE
6. Vaporciyan AA, Nesbitt JC, Lee JS, Stevens C, Komaki R, Roth JA. Neoplasms of the thorax. In:  Bast RC,  Kufe DW,  Pollock RE,  Weichselbaum RR,  Holland JF,  Frei E editor. Cancer Medicine. Ontario: BC Dekker Inc; 2000;p. 1227–1292
7. National Cancer Institute PDQ Statement . Non-small cell lung cancer (PDQ): treatment - health professionals. January 2002;
8. Giaccone G. Clinical perspectives on platinum resistance. Drugs. 2000;59:9–17
   • CrossRef
9. Medina-Gundrum L, Gomez L, Cerna C, et al.  ZD0473 exhibits marked in vitro anticancer activity in human tumor specimens. Eur J Cancer. 2001;37: Abst 454
10. Akiyama Y, Kusuba H, Kanzawa F. Overcoming cisplatin-resistance by ZD0473 (cis-amminedichloro[2-methylpyridine]platinum[II]) in human lung cancer cells. In: Poster presented at the 2^nd International Lung Cancer Congress. Hawaii, USA. July 18–21, 2001;
11. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer. 1998;77:366–373
    • MEDLINE
12. Kelland L, Judson I, Koehler M, Stephens T, Roberts D. Preclinical and clinical overview of the novel platinum complex, ZD0473 (cis-amminedichloro[2-methylpyridine]platinum[II]). Lung Cancer. 2000;70: Abst 227
13. Crino L, Tonato M, Darwish S, et al.  A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol. 1990;26:52–56
    • MEDLINE
    • CrossRef
14. Sandler AB, Nemunaitis J, Denham C, et al.  Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18:122–130
    • MEDLINE
15. Wozniak AJ, Crowley JJ, Balcerzak SP, et al.  Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol. 1998;16:2459–2465
    • MEDLINE
16. Fossella FV, DeVore R, Kerr RN, et al.  Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small-cell lung cancer study group. J Clin Oncol. 2000;18:2354–2362
    • MEDLINE
17. Shepherd FA, Dancey J, Ramlay R, et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103
    • MEDLINE
18. Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin Oncol. 2001;28:4–9
    • Abstract
    • Full-Text PDF (1227 KB)
    • CrossRef
19. von Pawel J, Schiller JH, Sheperd FA, et al.  Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–667
    • MEDLINE